1. Home
  2. SHMD vs IFRX Comparison

SHMD vs IFRX Comparison

Compare SHMD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

N/A

Current Price

$2.12

Market Cap

198.2M

Sector

N/A

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.18

Market Cap

225.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHMD
IFRX
Founded
1864
2007
Country
Germany
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.2M
225.5M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
SHMD
IFRX
Price
$2.12
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $8.41
AVG Volume (30 Days)
821.2K
★ 1.1M
Earning Date
11-25-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$49.82
N/A
Revenue Next Year
$48.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$0.80
52 Week High
$10.65
$2.95

Technical Indicators

Market Signals
Indicator
SHMD
IFRX
Relative Strength Index (RSI) 34.49 31.08
Support Level $2.09 $0.81
Resistance Level $3.65 $2.44
Average True Range (ATR) 0.25 0.15
MACD -0.01 -0.03
Stochastic Oscillator 2.83 3.12

Price Performance

Historical Comparison
SHMD
IFRX

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: